342 related articles for article (PubMed ID: 15891995)
1. The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization study.
Hicks DG; Yoder BJ; Pettay J; Swain E; Tarr S; Hartke M; Skacel M; Crowe JP; Budd GT; Tubbs RR
Hum Pathol; 2005 Apr; 36(4):348-56. PubMed ID: 15891995
[TBL] [Abstract][Full Text] [Related]
2. Topoisomerase IIalpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study.
Kanta SY; Yamane T; Dobashi Y; Mitsui F; Kono K; Ooi A
Hum Pathol; 2006 Oct; 37(10):1333-43. PubMed ID: 16949920
[TBL] [Abstract][Full Text] [Related]
3. Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples.
Mueller RE; Parkes RK; Andrulis I; O'Malley FP
Genes Chromosomes Cancer; 2004 Apr; 39(4):288-97. PubMed ID: 14978790
[TBL] [Abstract][Full Text] [Related]
4. Analysis of ERBB2 and TOP2A gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer.
Bouchalová K; Trojanec R; Kolár Z; Cwiertka K; Cernáková I; Mihál V; Hajdúch M
Neoplasma; 2006; 53(5):393-401. PubMed ID: 17013533
[TBL] [Abstract][Full Text] [Related]
5. Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer.
Orlando L; Del Curto B; Gandini S; Ghisini R; Pietri E; Torrisi R; Balduzzi A; Cardillo A; Dellapasqua S; Veronesi P; Viale G; Goldhirsch A; Colleoni M
Breast; 2008 Oct; 17(5):506-11. PubMed ID: 18456496
[TBL] [Abstract][Full Text] [Related]
6. Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer.
Konecny GE; Pauletti G; Untch M; Wang HJ; Möbus V; Kuhn W; Thomssen C; Harbeck N; Wang L; Apple S; Jänicke F; Slamon DJ
Breast Cancer Res Treat; 2010 Apr; 120(2):481-9. PubMed ID: 20130985
[TBL] [Abstract][Full Text] [Related]
7. Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients.
Kuo SJ; Wang BB; Chang CS; Chen TH; Yeh KT; Lee DJ; Yin PL; Chen M
Taiwan J Obstet Gynecol; 2007 Jun; 46(2):146-51. PubMed ID: 17638622
[TBL] [Abstract][Full Text] [Related]
8. Gene copy mapping of the ERBB2/TOP2A region in breast cancer.
Jacobson KK; Morrison LE; Henderson BT; Blondin BA; Wilber KA; Legator MS; O'Hare A; Van Stedum SC; Proffitt JH; Seelig SA; Coon JS
Genes Chromosomes Cancer; 2004 May; 40(1):19-31. PubMed ID: 15034864
[TBL] [Abstract][Full Text] [Related]
9. TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer.
Villman K; Sjöström J; Heikkilä R; Hultborn R; Malmström P; Bengtsson NO; Söderberg M; Saksela E; Blomqvist C
Acta Oncol; 2006; 45(5):590-6. PubMed ID: 16864174
[TBL] [Abstract][Full Text] [Related]
10. A subset of pancreatic adenocarcinomas demonstrates coamplification of topoisomerase IIalpha and HER2/neu: use of immunolabeling and multicolor FISH for potential patient screening andtreatment.
Hansel DE; Ashfaq R; Rahman A; Wanzer D; Yeo CJ; Wilentz RE; Maitra A
Am J Clin Pathol; 2005 Jan; 123(1):28-35. PubMed ID: 15762277
[TBL] [Abstract][Full Text] [Related]
11. Topoisomerase II-alpha gene deletion is not frequent as its amplification in breast cancer.
Park K; Han S; Gwak GH; Kim HJ; Kim J; Kim KM
Breast Cancer Res Treat; 2006 Aug; 98(3):337-42. PubMed ID: 16502015
[TBL] [Abstract][Full Text] [Related]
12. Low-level TOP2A amplification in prostate cancer is associated with HER2 duplication, androgen resistance, and decreased survival.
Murphy AJ; Hughes CA; Barrett C; Magee H; Loftus B; O'Leary JJ; Sheils O
Cancer Res; 2007 Mar; 67(6):2893-8. PubMed ID: 17363613
[TBL] [Abstract][Full Text] [Related]
13. Chromosome 17 centromere duplication and responsiveness to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Tibau A; López-Vilaró L; Pérez-Olabarria M; Vázquez T; Pons C; Gich I; Alonso C; Ojeda B; Ramón y Cajal T; Lerma E; Barnadas A; Escuin D
Neoplasia; 2014 Oct; 16(10):861-7. PubMed ID: 25379022
[TBL] [Abstract][Full Text] [Related]
14. Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer.
Järvinen TA; Tanner M; Bärlund M; Borg A; Isola J
Genes Chromosomes Cancer; 1999 Oct; 26(2):142-50. PubMed ID: 10469452
[TBL] [Abstract][Full Text] [Related]
15. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J
J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728
[TBL] [Abstract][Full Text] [Related]
16. ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction.
Brase JC; Schmidt M; Fischbach T; Sültmann H; Bojar H; Koelbl H; Hellwig B; Rahnenführer J; Hengstler JG; Gehrmann MC
Clin Cancer Res; 2010 Apr; 16(8):2391-401. PubMed ID: 20371687
[TBL] [Abstract][Full Text] [Related]
17. Fluorescence in situ hybridization (FISH) as primary methodology for the assessment of HER2 Status in adenocarcinoma of the breast: a single institution experience.
Tubbs RR; Hicks DG; Cook J; Downs-Kelly E; Pettay J; Hartke MB; Hood L; Neelon R; Myles J; Budd GT; Moore HC; Andresen S; Crowe JP
Diagn Mol Pathol; 2007 Dec; 16(4):207-10. PubMed ID: 18043283
[TBL] [Abstract][Full Text] [Related]
18. retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group.
Knoop AS; Knudsen H; Balslev E; Rasmussen BB; Overgaard J; Nielsen KV; Schonau A; Gunnarsdóttir K; Olsen KE; Mouridsen H; Ejlertsen B;
J Clin Oncol; 2005 Oct; 23(30):7483-90. PubMed ID: 16234514
[TBL] [Abstract][Full Text] [Related]
19. The topoisomerase II alpha gene status in primary breast cancer is a predictive marker of the response to anthracycline-based neoadjuvant chemotherapy.
Kawachi K; Sasaki T; Murakami A; Ishikawa T; Kito A; Ota I; Shimizu D; Nozawa A; Nagashima Y; Machinami R; Aoki I
Pathol Res Pract; 2010 Mar; 206(3):156-62. PubMed ID: 20089371
[TBL] [Abstract][Full Text] [Related]
20. Topoisomerase 2A gene amplification in breast cancer. Critical evaluation of different FISH probes.
Varga Z; Moelans CB; Zuerrer-Hardi U; Ramach C; Behnke S; Kristiansen G; Moch H
Breast Cancer Res Treat; 2012 Jun; 133(3):929-35. PubMed ID: 22083232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
